NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.


Journal

Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515

Informations de publication

Date de publication:
07 2023
Historique:
medline: 13 7 2023
pubmed: 12 7 2023
entrez: 11 7 2023
Statut: ppublish

Résumé

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.

Identifiants

pubmed: 37433432
doi: 10.6004/jnccn.2023.0035
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

694-704

Auteurs

Al B Benson (AB)

Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Michael I D'Angelica (MI)

Memorial Sloan Kettering Cancer Center.

Thomas Abrams (T)

Dana-Farber/Brigham and Women's Cancer Center.

Daniel E Abbott (DE)

University of Wisconsin Carbone Cancer Center.

Aijaz Ahmed (A)

Stanford Cancer Institute.

Daniel A Anaya (DA)

Moffitt Cancer Center.

Robert Anders (R)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Chandrakanth Are (C)

Fred & Pamela Buffett Cancer Center.

Melinda Bachini (M)

The Cholangiocarcinoma Foundation.

David Binder (D)

University of Colorado Cancer Center.

Mitesh Borad (M)

Mayo Clinic Comprehensive Cancer Center.

Christopher Bowlus (C)

UC Davis Comprehensive Cancer Center.

Daniel Brown (D)

Vanderbilt-Ingram Cancer Center.

Adam Burgoyne (A)

UC San Diego Moores Cancer Center.

Jason Castellanos (J)

Fox Chase Cancer Center.

Prabhleen Chahal (P)

Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Jordan Cloyd (J)

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

Anne M Covey (AM)

Memorial Sloan Kettering Cancer Center.

Evan S Glazer (ES)

The University of Tennessee Health Science Center.

William G Hawkins (WG)

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Renuka Iyer (R)

Roswell Park Comprehensive Cancer Center.

Rojymon Jacob (R)

O'Neal Comprehensive Cancer Center at UAB.

Lawrence Jennings (L)

Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

R Kate Kelley (RK)

UCSF Helen Diller Family Comprehensive Cancer Center.

Robin Kim (R)

Huntsman Cancer Institute at the University of Utah.

Matthew Levine (M)

Abramson Cancer Center at the University of Pennsylvania.

Manisha Palta (M)

Duke Cancer Institute.

James O Park (JO)

Fred Hutchinson Cancer Center.

Steven Raman (S)

UCLA Jonsson Comprehensive Cancer Center.

Sanjay Reddy (S)

Fox Chase Cancer Center.

Sean Ronnekleiv-Kelly (S)

University of Wisconsin Carbone Cancer Center.

Vaibhav Sahai (V)

University of Michigan Rogel Cancer Center.

Gagandeep Singh (G)

City of Hope National Medical Center.

Stacey Stein (S)

Yale Cancer Center/Smilow Cancer Hospital.

Anita Turk (A)

Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Jean-Nicolas Vauthey (JN)

The University of Texas MD Anderson Cancer Center.

Alan P Venook (AP)

UCSF Helen Diller Family Comprehensive Cancer Center.

Adam Yopp (A)

UT Southwestern Simmons Comprehensive Cancer Center.

Nicole McMillian (N)

National Comprehensive Cancer Network.

Ryan Schonfeld (R)

National Comprehensive Cancer Network.

Cindy Hochstetler (C)

National Comprehensive Cancer Network.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH